肥胖与呼吸机相关性肺炎的关系:NUTRIREA2试验的事后分析
本研究为NUTRIREA2开放标签随机对照试验的事后分析,纳入44个法国ICU中接受有创机械通气和升压药治疗的成人休克患者,比较早期肠内营养与肠外营养。肥胖定义为ICU入院时BMI≥30 kg/m2。
要点
- 在123例有胃蛋白酶和α-淀粉酶测量的亚组中,肥胖与非肥胖患者胃内容物或口咽分泌物大量微误吸率无显著差异。
- 该分析提示肥胖不应作为ICU内VAP风险分层或强化预防的唯一依据,但需注意事后分析的局限性。
适用人群与场景
- 纳入:NUTRIREA2试验中44个法国ICU的成人患者,接受有创机械通气和升压药支持治疗休克,并接受肠内或肠外营养。
- 排除:原文未提及具体排除标准。
- 场景:ICU(成人重症监护)。
- 病情阶段:休克需要升压药和机械通气的急性期。
诊断标准与关键阈值
- 肥胖定义:ICU入院时BMI ≥ 30 kg/m2。
- VAP诊断:由独立盲法委员会根据所有可用的临床、影像学和微生物学数据裁定,仅纳入首次VAP发作。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究设计:NUTRIREA2开放标签随机对照试验的事后分析,纳入44个法国ICU的2325例患者,其中699例(30%)有肥胖。
- 亚组分析:123例有胃蛋白酶和α-淀粉酶测量的患者中,肥胖与非肥胖组胃内容物或口咽分泌物大量微误吸率无显著差异。
证据类型、等级与局限
- 证据类型:随机对照试验的事后分析(post hoc analysis)。
- 证据等级或推荐强度:原文未提及。
- 局限:事后分析,结果需谨慎解读;原文未提及其他局限。
对床旁实践的改变
- 对于接受机械通气和升压药治疗的休克成人,肥胖(BMI≥30 kg/m2)不应单独作为增加VAP预防措施的依据。
- 该事后分析提示肥胖与VAP发生率无显著关联,但需注意研究设计为事后分析,不能等同于前瞻性验证。
- 原文未提及对VAP预防措施的具体改变。
指南或共识出处
- NUTRIREA2试验(Impact of Early Enteral vs Parenteral Nutrition on Mortality in Patients Requiring Mechanical Ventilation and Catecholamines),发表于Chest。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Patients with obesity are at higher risk for community-acquired and nosocomial infections. However, no study has specifically evaluated the relationship between obesity and ventilator-associated pneumonia (VAP).
RESEARCH QUESTION: Is obesity associated with an increased incidence of VAP?
STUDY DESIGN AND METHODS: This study was a post hoc analysis of the Impact of Early Enteral vs Parenteral Nutrition on Mortality in Patients Requiring Mechanical Ventilation and Catecholamines (NUTRIREA2) open-label, randomized controlled trial performed in 44 French ICUs. Adults receiving invasive mechanical ventilation and vasopressor support for shock and parenteral nutrition or enteral nutrition were included. Obesity was defined as BMI ≥ 30 kg/m2 at ICU admission. VAP diagnosis was adjudicated by an independent blinded committee, based on all available clinical, radiologic, and microbiologic data. Only first VAP episodes were taken into account. Incidence of VAP was analyzed by using the Fine and Gray model, with extubation and death as competing risks.
RESULTS: A total of 699 (30%) of the 2,325 included patients had obesity; 224 first VAP episodes were diagnosed (60 and 164 in obese and nonobese groups, respectively). The incidence of VAP at day 28 was 8.6% vs 10.1% in the two groups (hazard ratio, 0.85; 95% CI 0.63-1.14; P = .26). After adjustment on sex, McCabe score, age, antiulcer treatment, and Sequential Organ Failure Assessment at randomization, the incidence of VAP remained nonsignificant between obese and nonobese patients (hazard ratio, 0.893; 95% CI, 0.66-1.2; P = .46). Although no significant difference was found in duration of mechanical ventilation and ICU length of stay, 90-day mortality was significantly lower in obese than in nonobese patients (272 of 692 [39.3%] patients vs 718 of 1,605 [44.7%]; P = .02). In a subgroup of patients (n = 123) with available pepsin and alpha-amylase measurements, no significant difference was found in rate of abundant microaspiration of gastric contents, or oropharyngeal secretions between obese and nonobese patients.
INTERPRETATION: Our results suggest that obesity has no significant impact on the incidence of VAP.
参考来源
- Nseir S, Le Gouge A, Pouly O, et al. Relationship Between Obesity and Ventilator-Associated Pneumonia: A Post Hoc Analysis of the NUTRIREA2 Trial. Chest. 2021. PMID: 33561455. doi:10.1016/j.chest.2021.01.081
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。